Practice survey tumor pain

First published: 28/12/2017

Last updated: 31/03/2024

Study Finalised

Administrative details

PURI

https://redirect.ema.europa.eu/resource/22094

EU PAS number

EUPAS22093

Study ID

22094

DARWIN EU® study

No

Study countries

☐ Germany

Study description

Cross sectional online survey (based on validated German pain questionnaires) on cancer-related pain characertistics and treatment approaches among German patients.

Study status

Finalised

Research institutions and networks

Institutions

Institute of Neurological Sciences

Contact details

Study institution contact

Michael Ueberall

Study contact

michael.ueberall@ifnap.de

Primary lead investigator

Michael Ueberall

Primary lead investigator

Study timelines

Date when funding contract was signed
Planned: 31/12/2016

Actual: 31/12/2016

Study start date
Planned: 01/02/2017

Actual: 01/02/2017

Data analysis start date
Planned: 01/07/2017

Actual: 01/07/2017

Date of final study report
Planned: 14/07/2017

Actual: 14/07/2017

Sources of funding

- Other

More details on funding

German Pain Association

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Other

Study topic, other:

Disease/Epidemiology study

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Data collection methods:

Primary data collection

Main study objective:

To assess patient-reported information on the characteristics of cancer-related background and breakthrough pain, treatment approaches and interference with quality-of-life and daily life activities.

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Medical condition to be studied

Cancer pain

Population studied

Short description of the study population

All cancer patients suffering pain from Germany.

Age groups

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Special population of interest

Other

Special population of interest, other

Cancer patients

Estimated number of subjects

5000

Study design details

Data analysis plan

Descriptive analysis of the as-reported data.

Data management

Data sources

Data sources (types)

Patient surveys

Spontaneous reports of suspected adverse drug reactions

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown